Previous close | 27.03 |
Open | 27.01 |
Bid | 26.85 x 800 |
Ask | 27.60 x 1100 |
Day's range | 26.49 - 27.33 |
52-week range | 15.10 - 39.05 |
Volume | |
Avg. volume | 2,045,492 |
Market cap | 4.067B |
Beta (5Y monthly) | 2.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.00 (3.66%) |
Ex-dividend date | 23 Feb 2024 |
1y target est | N/A |
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours said on Thursday its chief financial officer, Jonathan Lock, had resigned on April 23 after the chemical firm revised certain past financial results following an internal review. Earlier this year, the internal review showed manipulation by some of its senior management to meet free cash flow targets tied to their incentives, resulting in its top three executives, including Lock and CEO Mark Newman, being placed on administrative leave. The review had identified "material weaknesses" in the company's internal control over financial reporting and resulted in revisions of its balance sheet as of Dec. 31, 2022 and its cash flow statements for 2021 and 2022.
Stepan Co. (SCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.